102
Participants
Start Date
February 1, 2016
Primary Completion Date
May 18, 2023
Study Completion Date
August 15, 2023
Melphalan/HDS
Melphalan (3 mg/kg IBW) with Hepatic Device System (HDS)
Universitair Ziekenhuis Leuven, Leuven
Universitätsklinikum Graz, Graz
UniversitätsSpital Zürich, Zurich
Charité Unversitätsmedizin Berlin Comprehensive Cancer Center, Berlin
Roswell Park Cancer Institute, Buffalo
Thomas Jefferson University, Philadelphia
Stanford University, Palo Alto
Istituto Europeo di Oncologia, Milan
Duke University Medical Center, Durham
Hospital Ramón y Cajal, Madrid
Emory University, Atlanta
Moffitt Cancer Center, Tampa
Universitätsklinikum Giessen und Marburg, Marburg
University of Tennessee Health Science Center, Memphis
Ohio State University James Cancer Center, Columbus
University of Chicago, Chicago
Centre Léon Bérard, Lyon
University of Arizona, Tucson
Universitätsklinikum Regensburg, Regensburg
Universitätsklinikum Würzburg, Würzburg
Universitätshautklinik Münster, Münster
Clínic Barcelona, Barcelona
University Hospital Southampton NHS Trust, Southampton
Aintree University Hospital, Liverpool
Collaborators (1)
IQVIA Biotech
INDUSTRY
Delcath Systems Inc.
INDUSTRY